Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese launch for Bayer Schering's Zevalin

This article was originally published in Scrip

Executive Summary

Bayer Yakuhin(Bayer Schering Pharma) has launched the antibody radio-immunotherapy Zevalin (ibritumomab tiuxetan) in Japan for the orphan indications of relapsed/refractory CD20-positive follicular low-grade or indolent B-cell non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma. The product, originally licensed from Biogen Idec by Schering AG, is labelled with either yttrium-90 or indium-111, which kill B-cells targeted by the CD20 antigen. The isotopes will be supplied by the Fujifilm subsidiary Fujifilm RI Pharma, with which Bayer has a local alliance. The therapy is the first of its type to be launched in Japan, where around 95% of lymphoma patients have NHL, of whom 70% present with the B-cell type.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts